BioTech Medics, Inc (BMCS) Fair Value & Analysis
Healthcare · US · Market cap $61.6K
BioTech Medics, Inc
BMCS · US
Fair value as of: Jun 26, 2026
From 3 valuation models · updated 7 days ago
Fair value updated Jun 26, 2026 — revised from $0.7300 to $0.0001 (−100.0%) since Jun 24, 2026. Share price −33.3% over the past month.
Price vs Fair Value (12 months)
12‑month range $0.0001 – $0.0070 · the $0.0001 price screens below the $0.0001 fair value. As of Jun 26, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
BioTech Medics, Inc (BMCS) currently trades at $0.0001, while our model-based Fair Value estimate is $0.0001 — implying the stock looks roughly 0.0% undervalued today. We read business quality at 33/100 (below-average quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: low) — always confirm before acting.
Trailing-twelve-month revenue stands at $470K. Fundamentals as of Jun 26, 2026
Key figures & financial health
Figures from reported company fundamentals (EODHD) · as of Jun 26, 2026. TTM = trailing twelve months.
About the company
BioTech Medics, Inc. operates as a medical-based holding company. The company operates medical therapeutic laser centers that treat various pain ailments affecting the muscles, nerves, and bones, as well as arthritis. It also offers SHBAN, an antiseptic hand and body sanitizer. In addition, the company develops and sells nutraceutical products, such as BioBody Balance, a liquid vitamin concentrate; and BioBody Energy Spray, a caffeine and alcohol free natural vitamin energy spray. It offers its nutraceutical products through gross retail sales. The company was incorporated in 1997 and is based in Southlake, Texas with laser pain centers in Texas, California, New Mexico, and Florida.
Revenue & earnings trend
FY2008 – FY2024 · reported fiscal years
BioTech Medics, Inc reported revenue of $470K in FY2011 versus $477K in FY2008, a compound −0.5%/yr. Reported net income was −$2.9K in FY2024.
Is BMCS fairly valued? → Check now
Similar stocks
6 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate (as of Jun 26, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Jiangsu Hengrui Pharmaceuticals Co 1276 | HK$57.85 | HK$29.84 | -48% |
| Sun Pharmaceutical Industries Limited SUNPHARMA | ₹1,786 | ₹991.46 | -44% |
| Zoetis Inc Z1TS34 | R$25.93 | R$19.70 | -24% |
| Hansoh Pharmaceutical Group 3692 | HK$29.30 | HK$23.90 | -18% |
| Divi's Laboratories Limited DIVISLAB | ₹6,639 | ₹1,281 | -81% |
| Swedish Orphan Biovitrum AB SOBI | kr 435.00 | kr 285.77 | -34% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is BioTech Medics, Inc (BMCS) undervalued?
What is the fair value of BMCS?
What is the quality score of BMCS?
What is the revenue of BioTech Medics, Inc (BMCS)?
What is the net profit margin of BMCS?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.